Logo image of BGXX

BRIGHT GREEN CORP (BGXX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BGXX - US10920G1004 - Common Stock

0.1481 USD
-0.04 (-22.01%)
Last: 9/18/2024, 8:00:00 PM
0.155 USD
+0.01 (+4.66%)
After Hours: 9/18/2024, 8:00:00 PM
Fundamental Rating

0

Overall BGXX gets a fundamental rating of 0 out of 10. We evaluated BGXX against 191 industry peers in the Pharmaceuticals industry. BGXX may be in some trouble as it scores bad on both profitability and health. BGXX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BGXX has reported negative net income.
BGXX had a negative operating cash flow in the past year.
BGXX had negative earnings in each of the past 5 years.
BGXX had a negative operating cash flow in each of the past 5 years.
BGXX Yearly Net Income VS EBIT VS OCF VS FCFBGXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -62.04%, BGXX is not doing good in the industry: 70.26% of the companies in the same industry are doing better.
The Return On Equity of BGXX (-100.53%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -62.04%
ROE -100.53%
ROIC N/A
ROA(3y)-75.05%
ROA(5y)-54.76%
ROE(3y)-129.62%
ROE(5y)-88.27%
ROIC(3y)N/A
ROIC(5y)N/A
BGXX Yearly ROA, ROE, ROICBGXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

BGXX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BGXX Yearly Profit, Operating, Gross MarginsBGXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for BGXX has been increased compared to 1 year ago.
BGXX has a better debt/assets ratio than last year.
BGXX Yearly Shares OutstandingBGXX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M
BGXX Yearly Total Debt VS Total AssetsBGXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

BGXX has an Altman-Z score of -3.41. This is a bad value and indicates that BGXX is not financially healthy and even has some risk of bankruptcy.
BGXX has a Altman-Z score of -3.41. This is comparable to the rest of the industry: BGXX outperforms 42.56% of its industry peers.
BGXX has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
BGXX has a Debt to Equity ratio of 0.05. This is comparable to the rest of the industry: BGXX outperforms 51.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -3.41
ROIC/WACCN/A
WACCN/A
BGXX Yearly LT Debt VS Equity VS FCFBGXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M 10M -10M

2.3 Liquidity

BGXX has a Current Ratio of 0.02. This is a bad value and indicates that BGXX is not financially healthy enough and could expect problems in meeting its short term obligations.
BGXX has a Current ratio of 0.02. This is amonst the worse of the industry: BGXX underperforms 99.49% of its industry peers.
BGXX has a Quick Ratio of 0.02. This is a bad value and indicates that BGXX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.02, BGXX is not doing good in the industry: 99.49% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
BGXX Yearly Current Assets VS Current LiabilitesBGXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.28% over the past year.
EPS 1Y (TTM)40.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BGXX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGXX Price Earnings VS Forward Price EarningsBGXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGXX Per share dataBGXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BGXX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIGHT GREEN CORP

NASDAQ:BGXX (9/18/2024, 8:00:00 PM)

After market: 0.155 +0.01 (+4.66%)

0.1481

-0.04 (-22.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2022-11-14/amc
Earnings (Next)N/A N/A
Inst Owners0.07%
Inst Owner Change0%
Ins Owners65.87%
Ins Owner Change0%
Market Cap28.16M
Revenue(TTM)N/A
Net Income(TTM)-9.92M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.86
P/tB 2.86
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.04%
ROE -100.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.05%
ROA(5y)-54.76%
ROE(3y)-129.62%
ROE(5y)-88.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.39%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -3.41
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)646.55%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.05%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y48.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y78.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.91%
OCF growth 3YN/A
OCF growth 5YN/A

BRIGHT GREEN CORP / BGXX FAQ

Can you provide the ChartMill fundamental rating for BRIGHT GREEN CORP?

ChartMill assigns a fundamental rating of 0 / 10 to BGXX.


What is the valuation status of BRIGHT GREEN CORP (BGXX) stock?

ChartMill assigns a valuation rating of 0 / 10 to BRIGHT GREEN CORP (BGXX). This can be considered as Overvalued.


Can you provide the profitability details for BRIGHT GREEN CORP?

BRIGHT GREEN CORP (BGXX) has a profitability rating of 0 / 10.